<Header>
<FileStats>
    <FileName>20241206_10-Q-A_edgar_data_1671858_0001193125-24-272445.txt</FileName>
    <GrossFileSize>397667</GrossFileSize>
    <NetFileSize>6464</NetFileSize>
    <NonText_DocumentType_Chars>137358</NonText_DocumentType_Chars>
    <HTML_Chars>100518</HTML_Chars>
    <XBRL_Chars>73698</XBRL_Chars>
    <XML_Chars>70102</XML_Chars>
    <N_Exhibits>7</N_Exhibits>
</FileStats>
<SEC-Header>
0001193125-24-272445.hdr.sgml : 20241206
<ACCEPTANCE-DATETIME>20241206160556
ACCESSION NUMBER:		0001193125-24-272445
CONFORMED SUBMISSION TYPE:	10-Q/A
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241206
DATE AS OF CHANGE:		20241206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARS Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001671858
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				811489190
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39756
		FILM NUMBER:		241532299

	BUSINESS ADDRESS:	
		STREET 1:		11682 EL CAMINO REAL, SUITE 120
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-771-9307

	MAIL ADDRESS:	
		STREET 1:		11682 EL CAMINO REAL, SUITE 120
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Silverback Therapeutics, Inc.
		DATE OF NAME CHANGE:	20160412

</SEC-Header>
</Header>

 0001193125-24-272445.txt : 20241206

10-Q/A
 1
 d864210d10qa.htm
 10-Q/A

10-Q/A 

UNITED STATES 

 SECURITIES AND EXCHANGE COMMISSION 

 Washington, D.C. 20549 

FORM 

Amendment No. 1 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 

 For the quarterly period ended 

 OR 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 

 For the transition period from 

to 

Commission File Number 

(Exact name of Registrant as specified in its Charter) 

(State or other jurisdiction of

 incorporation or organization)

(I.R.S. Employer

 Identification No.)

, 

 , 

(Address of principal executive offices)

(Zip Code)

 Registrant s telephone number, including area code: ) 

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class

Trading

 Symbol(s)

Name of each exchange

 on which registered

, par value 0.0001 per share

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15( d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. No 
 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
 during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). No 
 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
 filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2
 of the Exchange Act: 

Large accelerated filer 

Accelerated filer 

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
 Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2
 of the Exchange Act). Yes No 
 As of November 6, 2024 there were shares of registrant s common stock, 0.0001 par value per share, outstanding. 

PART II OTHER INFORMATION

Item 5. Other Information

, 

(3)

X 

, 

X 

(1)
 
 Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 
 10b5-1(c)
 
under the Exchange Act.

(2)
 
 Non-Rule
 
 10b5-1
 
trading arrangement as defined in Item 408(c) of Regulation 
 S-K
 
under the Exchange Act.

(3)
 
 Represents the termination of a trading plan intended to satisfy the affirmative defense conditions of Rule 
 10b5-1(c)
 
adopted on March 31, 2023 and amended on December 8, 2023.

1

Item 6. Exhibits 

Exhibit Number 
 
 Description 

31.1 
 
 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 

31.2 
 
 Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 

101.INS 
 
 Inline XBRL Instance Document the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document 

101.SCH 
 
 Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents 

104 
 
 Cover page formatted as Inline XBRL and contained in Exhibit 101 
 
 2 

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 

ARS PHARMACEUTICALS, INC. 

Date: December 6, 2024 

By: 
 
 /s/ Richard Lowenthal, M.S., MSEL 

Richard Lowenthal, M.S., MSEL 

President and Chief Executive Officer 

(Principal Executive Officer) 

Date: December 6, 2024 

By: 
 
 /s/ Kathleen D. Scott 

Kathleen D. Scott 

Chief Financial Officer 

(Principal Financial and Accounting Officer) 
 
 3 

<EX-31.1>
 2
 d864210dex311.htm
 EX-31.1

EX-31.1 

Exhibit 31.1 
 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 
 SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 
 I, Richard Lowenthal, certify that: 1. I have reviewed this
Amendment No. 1 to the Quarterly Report on Form 10-Q/A for the quarter ended September 30, 2024 of ARS Pharmaceuticals, Inc.; and 
 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report. 

Date: December 6, 2024 

By: 
 
 /s/ Richard Lowenthal, M.S., MSEL 

Richard Lowenthal, M.S., MSEL 

President and Chief Executive Officer 

(Principal Executive Officer) 

</EX-31.1>

<EX-31.2>
 3
 d864210dex312.htm
 EX-31.2

EX-31.2 

Exhibit 31.2 
 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 
 SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 
 I, Kathleen Scott, certify that: 1. I have reviewed this
Amendment No. 1 to the Quarterly Report on Form 10-Q/A for the quarter ended September 30, 2024 of ARS Pharmaceuticals, Inc.; and 
 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report. 

Date: December 6, 2024 

By: 
 
 /s/ Kathleen D. Scott 

Kathleen D. Scott 

Chief Financial Officer 

(Principal Financial and Accounting Officer) 

</EX-31.2>

<EX-101.SCH>
 4
 spry-20240930.xsd
 XBRL TAXONOMY EXTENSION SCHEMA

</EX-101.CAL>

<EX-101.DEF>
 6
 spry-20240930_def.xml
 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE

</EX-101.DEF>

<EX-101.LAB>
 7
 spry-20240930_lab.xml
 XBRL TAXONOMY EXTENSION LABEL LINKBASE

</EX-101.LAB>

<EX-101.PRE>
 8
 spry-20240930_pre.xml
 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

</EX-101.PRE>

